Results 51 to 60 of about 5,351 (123)

Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant \u3ci\u3eAcinetobacter baumannii\u3c/i\u3e Infections

, 2023
OBJECTIVE: To review the pharmacology, efficacy, and safety of intravenous sulbactam-durlobactam (SUL-DUR) in the treatment of carbapenem-resistant DATA SOURCES: PubMed databases and ClinicalTrials.gov were searched using the following terms: Sulbactam ...
Kale-Pradhan, Pramodini B, Matlob, Andrew, August, Benjamin A   +2 more
core   +1 more source

Efficacy and safety of antibiotics in the treatment of multidrug-resistant Acinetobacter baumannii infections: A systematic review and Bayesian network meta-analysis

Journal of Global Antimicrobial Resistance
: Objectives: This study aims to compare the efficacy and safety of antimicrobial regimens for multidrug-resistant Acinetobacter baumannii (MDR A. baumannii) infections using a Bayesian network meta-analysis (NMA).
Binh Van Tran, Phi Yen Huynh, Tu Tuan Tran, Bao Bui Hoang, Ka-Wai Tam   +4 more
doaj   +1 more source

Synthesis and Evaluation of Carbapenem/Metallo‐β‐Lactamase Inhibitor Conjugates

ChemMedChem, Volume 19, Issue 21, November 4, 2024.
We report the synthesis and evaluation of molecular conjugates that combine a carbapenem antibiotic (meropenem or ertapenem) with a recently reported indole carboxylate scaffold. These hybrids are potent inhibitors of metallo‐β‐lactamases including the clinically relevant NDM‐1 and IMP‐1 enzymes.
Mei‐Ling Gao, Ioli Kotsogianni, Foteini Skoulikopoulou, Nora C. Brüchle, Paolo Innocenti, Nathaniel I. Martin   +5 more
wiley   +1 more source

Microbiological eradication of XDR Acinetobacter baumannii intra-abdominal infection using sulbactam-durobactam: clinical and microbiological outcomes amidst irreversible host comorbidities

Frontiers in Medicine
BackgroundThe management of extensively drug-resistant (XDR) Acinetobacter baumannii (CRAB) in deep-seated infections remains a critical challenge, particularly when compounded by severe host comorbidities.Case presentationWe report the case of a 63-year-
Lei Yu, Jieli He, Waiming Chan, Waiming Chan, Shan Zou, Qingshan Zhou, Jun Jin   +6 more
doaj   +1 more source

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

British Journal of Pharmacology, Volume 181, Issue 11, Page 1553-1575, June 2024.
Abstract In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer.
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill A. Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

Epidemiology and clinical significance of carbapenemases in Australia: a narrative review

Internal Medicine Journal, Volume 54, Issue 4, Page 535-544, April 2024.
Abstract Carbapenemase‐producing gram‐negative bacteria (CP‐GNB) infections threaten public health with high mortality, morbidity and treatment costs. Although frequencies remain low in Australia (total number of CP‐GNB infections reported was 907 in 2022), blaIMP‐4 has established low levels of endemicity in many states.
Abdullah Tarik Aslan, David L. Paterson
wiley   +1 more source

The role of sulbactam-durlobactam in treating carbapenem-resistant Acinetobacter infections

Purpose of reviewInfections caused by multidrug-resistant Acinetobacter baumannii present a significant global health challenge. Available treatment options are limited and frequently constrained by unfavourable safety and pharmacokinetic profiles ...
Castaldo, Nadia, Vena, Antonio, Bassetti, Matteo, Giacobbe, Daniele Roberto   +3 more
core   +1 more source

Multidrug-Resistant Acinetobacter baumannii: Resistance Mechanisms, Emerging Therapies, and Prevention—A Narrative Review

Antibiotics
Acinetobacter baumannii is a leading intensive care unit (ICU) pathogen associated with high rates of carbapenem resistance and poor clinical outcomes.
Ioana Adelina Stoian, Bianca Balas Maftei, Carmen-Elena Florea, Alexandra Rotaru, Constantin Aleodor Costin, Maria Antoanela Pasare, Radu Crisan Dabija, Carmen Manciuc   +7 more
doaj   +1 more source

in a critically ill burn patient: clinical challenges and molecular characterization

, 2023
Background Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are associated with high mortality rates. The optimal treatment regimen for CRAB has not been defined.
Riccardi, Niccolò, Federica Limongi, Tiseo, Giusy, Nicastro, Manuela, Simona Barnini, Valentina Galfo, Barnini, Simona, Giordano, Cesira, Galfo, Valentina, Niccolò Riccardi, Limongi, Federica, Manuela Nicastro, Giusy Tiseo, Leonildi, Alessandro, Cesira Giordano, Alessandro Leonildi, Marco Falcone, Falcone, Marco   +17 more
core   +1 more source

Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline

Microorganisms
Acinetobacter baumannii complex (ABC) can result in a panoply of severe syndromes, including pneumonia and septic shock. Options available for treating infections caused by ABC and, more importantly, by carbapenem-resistant ABC (CRAB) are limited because
Noayna Arshad, Wael Azzam, Marya D. Zilberberg, Andrew F. Shorr   +3 more
doaj   +1 more source